Defining the role of cancer-risk genes in Type 2 diabetes pathogenesis

Defining the role of cancer-risk genes in Type 2 diabetes pathogenesis - Cancer risk genes in type 2 diabetes pathogenesis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36169

Enrollment

Registered

2012-06-01

Start date

2012-10-08

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dragers van een p16-gen mutatie diabetes mellitus

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: carrier of a CDKN2A (p16) mutation and partners or relatives without a CDKN2A-mutation

Exclusion criteria

Exclusion criteria: Being unwell or unable to give informed consent. Patients with dabetes mellitus

Design outcomes

Primary

Measure	Time frame
Do people with mutations in certain cancer*risk genes (CDKN2A) have altered glucose tolerance.	—

Countries

Netherlands

Outcome results